Click image to enlargeA Phase 4, Multicenter, 2-part Study Composed of a 1-Year Randomized, Double-blind, Parallel-group, Placebo-controlled, Active-comparator, Dose-optimization Evaluation followed by a 1-Year Open-label Evaluation to Assess the Safety and Efficacy of Guanfacine Hydrochloride Prolonged-release (SPD503) in Children and Adolescents aged 6 to 17 Years with Attention-deficit/Hyperactivity Disorder
Criteria:-Be between the ages of 6-17 years old
-Be sufferring from ADHD or already be diagnosed by a doctor
-Prior stimulant therapy did not work or was not suitable for your child or tolearted
-A parent or legal guardian who will bring the child or adolescent in for each visit and oversee their participation in the study and ensure they follow all the study procedures
-Child or adolescent should not have any issues swallowing tablets or capsules
-Child or adolescent should not have any issues with blood draws, we will need to collect a few blood samples occassionaly throughout the study.